RE:FrustratingThanks rvxeasystreet...excellent perspective.
I like your focus on the positive Assure results. The MACE findings would seem to be of huge significance to health, extending life expectancy and quality of life for thousands of patients.
There appears potentially to be many other health benefits to rvx-208 and based on what I've read, not being a health expert, IMO, there really seems like there is strong upside. Bengtpress and biotech always give us reality checks on the science but I think they see some potential benefits.
I guess none of us are "in the know". I'm certainly not because I'm new to this. I value the opinions of those who have had converstaions with DM and Dr. Wong. Body language and direct discussions are far more revealing than any webcast could achieve. From what I recall, those that have spoken to the key players seem to have positive hopes for rvx-208.
So the science seems hopeful. MACE results need to be replicated. The diabetes trial could be positive as could Alzheimers.
On the business side the chess game it is difficult to read. My sense is that there is a very strong belief by insiders that rvx-208 has legs and the P2c will get funded. The issue is when and how.
I find it very interesting that there are
no rumours or leaks about activity regarding deals. I understand everything must be kept close to the vest.
You posters do great research in digging on the scientific side, the financial side, the ownership structure, etc
but there are no leaks. Isn't it odd or am I not checking the right sites.
This suggests to me, I think as Sanfran says, they've been working on the deal for a long time and perhaps with a couple of options.
They seem to have set the priority on rvx-208 with the restructuring or introduction of the waiver between Zenith and RVX. I see this as disentanglement or freeing up each organization.
The reason I'm saying they put priority on rvx-208 is because last April, 2013, when they structured
for Spinco I was happy and expected to see IPO(s) happening fast on epigenetics. Well, it's been delayed 18 months. I recognize that things are happening and $8mm has been sourced for Zenith and I recognize the value that Eastern and NGN bring financially and also intellectualy.
I'm not very happy about having my (selfish) liquidity in Zenith locked up for 18 months or more.
So this delay at Zenith suggests to me they have been spending there business intellectual resources on a 208 deal.
Now, a previous post either today or yesterday, suggested one of the BPs is moving on epigenetics and I think I remember that Bayer already as a CVR with a private epigenetics USA based company.
Don better get moving on it or hire some help to make the IPOs happen.
I'm wondering why DM said in the Feb webcast for Zenith something to the effect that we'll do the IPO when the time is right. Is it because;
- They have not established the research base/credentials to justify an IPO? If so, this is not good.
- Or for financial reasons?
- Or for structural (share structure) reasons?
- Or...other resasons?
My bottom line, being a newbie, is, a deal on rvx-208 must be happening, IMO.
Cheers
Toinv